Nanotechnology Stocks To Keep An Eye On – April 25th

OSI Systems, NVE, and Clene are the three Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of NASDAQ OSIS traded down $0.98 during midday trading on Friday, reaching $201.33. The company had a trading volume of 40,558 shares, compared to its average volume of 184,730. The firm’s fifty day moving average price is $192.89 and its 200-day moving average price is $177.00. The company has a quick ratio of 1.25, a current ratio of 1.88 and a debt-to-equity ratio of 0.56. OSI Systems has a one year low of $126.57 and a one year high of $220.00. The stock has a market cap of $3.38 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 1.81 and a beta of 1.19.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVEC stock traded down $0.05 during midday trading on Friday, hitting $57.79. The company had a trading volume of 4,291 shares, compared to its average volume of 22,327. The stock has a market cap of $279.53 million, a price-to-earnings ratio of 18.64 and a beta of 1.05. NVE has a 52 week low of $51.50 and a 52 week high of $89.98. The stock’s 50 day moving average price is $63.86 and its 200 day moving average price is $72.96.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNN stock traded down $0.16 during mid-day trading on Friday, reaching $3.02. The stock had a trading volume of 77,387 shares, compared to its average volume of 77,553. The stock’s 50-day moving average price is $3.71 and its two-hundred day moving average price is $4.53. The firm has a market capitalization of $25.92 million, a PE ratio of -0.57 and a beta of 0.46. Clene has a 52-week low of $2.57 and a 52-week high of $9.20.